Especially at the most serious stage of GVHD from day 21 to day 28, significantly fewer CXCR3+ T cells were found in SLOs of GVHD+Fluvastatin mice compared to control mice (Figure 5(e)). Here, CXCR3 is linked to graft versus host disease.